HRT for Women With PCOS: Perimenopause, Postmenopause, and Every Stage Between

Published Jul 14, 2025Updated Sep 30, 2026Last reviewed Jul 14, 2025

9 linked public sourcesEditorial, sourcing, and corrections policy

Women with PCOS can be considered for menopausal hormone therapy using the same core questions as other women: which symptoms need treatment, whether the uterus is present, and how age and medical history affect the choice. PCOS adds a reason to keep metabolic follow-up organized; it does not identify one HRT prescription for everyone. [1,2]

Menopausal HRT and the combined contraceptive pill are different treatments. This page focuses on estrogen-based treatment for menopausal symptoms and how an existing PCOS history fits into that discussion.

How do you recognize perimenopause when periods have always been irregular?

Record new hot flashes, night sweats, sleep disruption and vaginal symptoms alongside the menstrual pattern. The change from your own baseline is useful, especially when irregular cycles predate midlife.

NICE generally identifies menopause clinically in otherwise healthy people aged 45 or older with typical symptoms, including after hysterectomy. It does not recommend two FSH tests for everyone with PCOS or no uterus. FSH is considered in selected younger age groups or diagnostic situations; combined hormonal contraception makes it unsuitable for identifying menopause. [3]

Bring the names of any hormonal medicines, past ovarian surgery and the approximate dates symptoms changed. Those details help determine whether testing would answer a useful question.

What symptoms can HRT treat?

Systemic estrogen is effective for menopausal hot flashes and night sweats. When vaginal dryness is the main problem, local vaginal estrogen is a separate option with much lower systemic exposure. Treatment selection starts with the symptom you want to improve. [1]

For example, a woman whose main difficulty is waking repeatedly with night sweats has a different treatment goal from someone seeking help for vaginal discomfort alone. Make those goals explicit at the initial visit and return to them when reviewing the response.

The Menopause Society describes a generally favorable balance for appropriately selected women starting treatment before age 60 or within 10 years of menopause. Starting later requires a fuller assessment of health history and the reason for treatment. HRT is not a treatment plan for PCOS-related glucose or cholesterol abnormalities by itself. [1]

How does having a uterus change the prescription?

Systemic estrogen is usually paired with a progestogen when the uterus is present. Sequential regimens use progestogen for part of the month; continuous combined regimens use it daily. The dose and duration must match the estrogen regimen. [4]

Micronized progesterone is one option. A suitable levonorgestrel intrauterine system may also provide endometrial protection, with its product, insertion date and intended duration checked by the prescriber. The British Menopause Society describes these alternatives in its prescribing guidance. [4]

After total hysterectomy, estrogen-only therapy is generally used. The operation type and reason for surgery still belong in the review. “Hysterectomy” should not be assumed to mean that the ovaries were removed or that every subsequent hormone decision is identical. [3,4]

For local low-dose vaginal estrogen, routine added progestogen is generally not needed. This differs from systemic estrogen treatment. [9]

Is transdermal estrogen always the best choice for PCOS?

Patches and gels are useful options, particularly when clotting risk or metabolic considerations make oral estrogen less attractive. The choice should follow the person's actual health history, rather than an invented rule that two PCOS risk factors require a particular regimen. Oral estrogen is associated with a greater clotting risk than transdermal treatment. [1,3]

One directly relevant PCOS study compared oral and transdermal estrogen, both combined with cyproterone acetate, in 24 women for three months. Their average age was about 25, not menopausal. Insulin sensitivity worsened in the oral group and did not change significantly in the transdermal group. It was not a trial showing that transdermal menopausal HRT improves insulin sensitivity in older women with PCOS. [5]

That distinction keeps the treatment decision focused on the patient rather than a misquoted study. Ask why the proposed route fits your symptoms, triglycerides, blood pressure, clotting history and preferences.

What metabolic follow-up does PCOS require?

The 2023 international PCOS guideline recommends:

Blood pressure measurement annually.
Glycemic reassessment every one to three years, adjusted for individual diabetes risk.
A lipid profile at diagnosis, with subsequent frequency based on the results and overall risk.
A 75-g oral glucose tolerance test as the most accurate glycemic assessment; fasting glucose or HbA1c are alternatives when it cannot be performed. [2]

Existing diabetes, abnormal results or medication changes may call for a different schedule. Starting HRT does not automatically create a need for the same full laboratory panel every three or six months in every woman.

Separate the HRT review from metabolic testing: one asks whether symptoms and tolerability have improved; the other follows the person's PCOS and cardiovascular health. Put both on the care plan so neither is overlooked.

What should happen if bleeding occurs on HRT?

Describe when bleeding began, its amount, the regimen and any missed progestogen doses. The British Menopause Society's guidance uses timing, bleeding pattern and endometrial risk factors to select the next step. Not every early episode requires an immediate biopsy. [6]

Bleeding that first appears more than six months after starting HRT or more than three months after changing it generally prompts ultrasound assessment under that guidance. Heavy or prolonged bleeding and relevant risk factors can justify earlier investigation. Ultrasound findings and the clinical picture then guide whether biopsy or hysteroscopy is needed. [6]

Report unexpected postmenopausal bleeding instead of assuming PCOS explains it. Likewise, a routine ultrasound before HRT is not a substitute for investigating new symptoms later.

Can testosterone help with low desire?

The ISSWSH guideline supports consideration of testosterone for appropriately assessed hypoactive sexual desire disorder. A testosterone level alone does not diagnose the problem. Assessment also considers pain, relationship factors, mood and medicines. [7]

For someone with PCOS, current androgen symptoms matter: the guideline advises against testosterone when clinical androgen excess, such as hirsutism, acne or androgenic alopecia, is present. If treatment is selected, baseline testosterone and SHBG and subsequent monitoring help avoid excessive exposure. Testosterone is commonly rechecked three to six weeks after starting. [7]

This is a separate treatment decision, not a routine ingredient to add to every HRT prescription.

What belongs in the next appointment?

Bring a symptom and bleeding timeline, the exact hormone products, recent relevant results and your surgical history. Agree on the treatment goal, how each medicine is taken and when the response will be reviewed.

History of breast cancer, blood clots, liver disease or unexplained bleeding changes the systemic-HRT assessment. New chest pain, sudden breathing difficulty, a swollen painful leg or sudden neurological symptoms need urgent assessment rather than waiting for a routine HRT review. [1,8]

A useful plan names the symptoms being treated, the prescription chosen and the follow-up that fits your health history.

References

Evidence overview for HRT for Women With PCOS: Perimenopause, Postmenopause, and Every Stage Between